Findings
Measurement variability arises from different wearable sensor placements, algorithms, and environmental contexts.
Standardized ontologies are needed to ensure consistency in physical activity measurement across digital health studies.
Regulatory agencies, including the FDA, have endorsed specific digital measures such as MVPA as clinical trial endpoints.
Advances in sensor technology and data analysis have improved the feasibility of measuring real-world physical activity with high accuracy.
Additional validation efforts are required for postural sway measures, as current technologies primarily rely on force plates and laboratory-based assessments.

Recommendations
Researchers and developers should adopt standardized ontologies to enhance the comparability of digital measures in clinical research.
Sensor placement and algorithm transparency must be considered to minimize measurement variability in digital endpoints.
Stakeholders should engage with regulatory bodies early to ensure that digital biomarkers meet evidentiary requirements for clinical trials.
Digital health technology developers should prioritize usability and patient-centered design to increase adoption and adherence.
Further research is needed to expand real-world applicability and validation of postural sway measures for clinical and therapeutic use.

Regulatory Considerations
FDA has recognized certain digital measures, such as time spent in MVPA, as valid clinical trial endpoints.
Digital measures used in clinical research should align with HL7 and industry standards for interoperability and data integrity.
Transparency in data processing, including raw data versus processed metrics, is essential for regulatory acceptance.
Developers must ensure compliance with data privacy regulations when collecting real-world physical activity data.
Post-market monitoring of digital endpoints is recommended to ensure continued accuracy and reliability in diverse patient populations.

Findings
No uniform definition exists for nocturnal scratching, leading to inconsistencies in data interpretation and measurement across studies.
There are significant differences in how scratching behaviors are defined, recorded, and analyzed, making cross-study comparisons difficult.
The term “nocturnal” is often used imprecisely, as sleep periods vary among individuals (e.g., shift workers, patients with disrupted sleep patterns).
Traditional methods such as videography and clinician observations are expensive, labor-intensive, and impractical for widespread use.
Advances in sensor-based wearables and machine learning present opportunities to create objective, scalable, and patient-centric digital measurement tools.

Recommendations
Define nocturnal scratching as a rhythmic and repetitive skin-contact movement occurring within a delimited sleep period, rather than restricting it to nighttime.
Implement standardized ontologies to guide measurement definitions, ensuring consistency across studies and clinical applications.
Encourage the creation and validation of wearables and machine learning algorithms for objective, scalable measurement of scratching.
Engage researchers, clinicians, patients, and regulatory bodies to drive consensus on measurement definitions and methodologies.
Establish digital measures as key endpoints in clinical trials, supporting their validation and regulatory acceptance.

Findings
The glossary establishes consistent terminology for digital health technologies, improving clarity in clinical research.
Definitions cover key aspects of digital measurement, including accuracy, precision, and validation.
Data integrity, security, and authentication are emphasized, particularly regarding structured and real-time data.
The glossary distinguishes between raw and processed data, providing clarity on data attribution and authenticity.
It includes terms relevant to both consumer-grade and regulated medical devices, supporting their appropriate use in clinical trials.

Findings
Lack of regulatory guidance on validating precision and reliability of DHT data.
Challenges in managing large, complex datasets without appropriate processing.
Insufficient integration of DHTs into existing clinical trial standards.

Recommendations
Develop a metadata set to improve data interpretability and exchangeability.
Encourage standard development organizations to extend existing standards for DHTs.
Ensure that none of the proposed metadata is compulsory, allowing flexibility based on application and resources.

Regulatory Considerations
Meet additional regulatory standards for medical devices.
Utilize guides like the FDA's Clinical Trials Transformation Initiative for data capture.
Align metadata standards with regulatory requirements to facilitate approval.